1-6 of 6
Karim Iskander
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States

Juliana E. Hidalgo-Lopez, Gail J. Roboz, Brent Wood, Michael Borowitz, Elias J. Jabbour, Kelly Velasco, Ehab Elkhouly, Babatunde Adedokun, Faraz Zaman, Karim Iskander, Aaron C. Logan
Journal: Blood
Blood (2021) 138 (Supplement 1): 4478.
https://doi.org/10.1182/blood-2021-144353
Published: 2021
Journal Articles

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Ola Landgren, MD PhD, Michel Attal, MD PhD, Dickran Kazandjian, MD, Murielle Roussel, MD, Jagoda K. Jasielec, MD, Dominik Dytfeld, Aparna Anderson, Tara Kervin, Karim Iskander, Khalid Mezzi, Tim Welliver, Akeem Yusuf, PhD BPharm, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1891.
https://doi.org/10.1182/blood-2019-127076
Published: 2019
Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study

Ola Landgren, MD PhD, David S Siegel, MD PhD, Daniel Auclair, PhD, Ajai Chari, MD, Michael Boedigheimer, Tim Welliver, MD PhD, Khalid Mezzi, Karim Iskander, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 799.
https://doi.org/10.1182/blood-2018-99-112289
Published: 2018
Journal Articles

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Philippe Moreau, A Keith Stewart, MB, ChB, Antonio Lazzaro, Meletios A Dimopoulos, MD, Michele Cavo, MD, Sikander Ailawadhi, Karim Iskander, Mei Huang, Anita Zahlten-Kumeli, Maria-Victoria Mateos, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3244.
https://doi.org/10.1182/blood-2018-99-114863
Published: 2018
Journal Articles

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Shaji K. Kumar, MD, Alan Fu, PhD MPH, Khalid Mezzi, Megan Braunlin, Christopher Kim, PhD, Karim Iskander, Ruben Niesvizky, MD, Sundar Jagannath, MD, Ralph Boccia, MD, Noopur Raje, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3253.
https://doi.org/10.1182/blood-2018-99-113519
Published: 2018
Journal Articles

Once-Weekly Carfilzomib with Dexamethasone Demonstrated Promising Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Age and Prior Bortezomib Exposure

Jesus G. Berdeja, MD, Robert M. Rifkin, MD, Roger Lyons, MD, Hui Yang, Anita Zahlten-Kuemeli, Sanjay K. Aggarwal, Karim Iskander, PhD, James Berenson, MD
Journal: Blood
Blood (2016) 128 (22): 2129.
https://doi.org/10.1182/blood.V128.22.2129.2129
Published: 2016